Sei Investments Co. Has $1.36 Million Stake in DBV Technologies S.A. (DBVT)
Sei Investments Co. cut its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 11.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 38,038 shares of the company’s stock after selling 5,000 shares during the period. Sei Investments Co. owned about 0.08% of DBV Technologies worth $1,358,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Victory Capital Management Inc. acquired a new stake in shares of DBV Technologies during the first quarter valued at $303,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of DBV Technologies during the first quarter valued at $471,000. Sit Investment Associates Inc. acquired a new stake in shares of DBV Technologies during the second quarter valued at $698,000. Jane Street Group LLC acquired a new stake in shares of DBV Technologies during the first quarter valued at $853,000. Finally, Bank of America Corp DE boosted its stake in shares of DBV Technologies by 86.3% in the first quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock valued at $936,000 after buying an additional 12,309 shares in the last quarter. 45.52% of the stock is currently owned by institutional investors.
DBV Technologies S.A. (NASDAQ:DBVT) opened at 44.04 on Wednesday. The stock’s 50 day moving average is $43.12 and its 200 day moving average is $36.84. The firm’s market cap is $2.03 billion. DBV Technologies S.A. has a one year low of $31.87 and a one year high of $46.33.
COPYRIGHT VIOLATION WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/30/sei-investments-co-has-1-36-million-stake-in-dbv-technologies-s-a-dbvt.html.
Several brokerages recently weighed in on DBVT. BidaskClub cut shares of DBV Technologies from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Zacks Investment Research raised shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a research report on Tuesday. Leerink Swann upped their price target on shares of DBV Technologies from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Friday, August 25th. ValuEngine raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price target on shares of DBV Technologies in a research report on Thursday, June 1st. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $50.00.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Want to see what other hedge funds are holding DBVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DBV Technologies S.A. (NASDAQ:DBVT).
Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.